ZAI LAB (09688) saw its stock soar by 5.50% during intraday trading on Thursday, as part of a broader rally in the pharmaceutical sector on the Hong Kong stock exchange. The significant uptick in ZAI LAB's share price aligns with the overall positive sentiment observed across various pharma stocks.
The pharmaceutical sector experienced a notable surge, with multiple companies recording substantial gains. While specific catalysts for the sector-wide rally were not immediately clear, investors appeared to show renewed interest in pharma stocks, possibly due to favorable market conditions or positive industry developments.
Among the top performers, Sino Biopharm led the pack with an impressive 13% increase. Other notable gainers included Immunotech, which matched ZAI LAB's 5% rise, while Dualitybio and Grand Pharma both advanced by 4%. Additionally, Ascletis, Remegen, and Beigene each saw their shares climb by 3%, further underscoring the broad-based nature of the pharma sector's rally.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。